All In Biotech

Drug Trial Radar · NCT06781567

Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma

A Phase Il Clinical Study to Evaluate the Efficacy and Safety of HG146 Capsules in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma.

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Dec 13, 2024

Primary completion

Dec 31, 2028

Study completion Jun 30, 2029

Sponsor

Lead sponsor
HitGen Inc.Industry
Sponsor type
Industry
First posted
Jan 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, open-label, non-randomized, multicenter study to evaluate the clinical efficacy and safety of HG146 in participants with recurrent or metastatic adenoid cystic carcinoma. This study is divided into two stages. 40 participants will be enrolled in the first stage. The efficacy and safty data will apply to make go or no go decision. Then the second stage will continue to enroll 100 Particapants.

Conditions

  • Adenoid Cystic Carcinoma
  • Head and Neck Cancer

Interventions

  • HG146Drug

    HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. objective response rate (ORR)Time frame: From enrollment to the end of treatment at 4 weeks
  2. 6 Months Progression-Free Survival (PFS)Time frame: From enrollment to treatment at 6 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Oriental Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.